Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy

Evan C Klein; Jack Rubinstein; Jennifer L Strande

doi:10.1016/j.jaccas.2019.07.008

Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy

JACC Case Rep. 2019 Aug 21;1(2):213-217. doi: 10.1016/j.jaccas.2019.07.008. eCollection 2019 Aug.

Authors

Evan C Klein¹, Jack Rubinstein², Jennifer L Strande^{1

3}

Affiliations

¹ Division of Cardiovascular Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
² Division of Cardiovascular Medicine, University of Cincinnati, Cincinnati, Ohio.
³ Department of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin.

Abstract

A 56-year-old man with multiple cardiac manifestations of type 1 myotonic dystrophy, including severe, nonischemic cardiomyopathy, presented in refractory cardiogenic shock requiring inotropic therapy. Given his wishes to die without having any intravenous medications, he was started on oral probenecid therapy, which allowed for successful elimination of his intravenous therapies. (Level of Difficulty: Intermediate.).

Keywords: CTG, cytosine-thymineguanine; CUG, cytosine-uracil-guanine; DM1, type 1 myotonic dystrophy; INR, international normalized ratio; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association; RNA, ribonucleic acid; SVC, superior vena cava; TRPV-2, transient receptor potential vanilloid-2 subtype; cardiogenic shock; cardiomyopathy; heart failure; inotropes; myotonic dystrophy; probenecid.

Publication types

Case Reports